These post-hoc analyses support the efficacy profile of DZP but are not from a pre-specified endpoint or regulatory submission. The next catalyst is the ongoing Phase 3 program; watch for regulatory filing plans and any pre-submission meetings with health authorities.
Drug in focus
BIIB drug pipeline →dapirolizumab pegol
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If the PHOENYCS FLY study reads out positively in December 2026, regulatory submissions (BLA in the US, MAA in Europe) could follow in 2027, with potential approval in 2028-2029, assuming no additional trials are required.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the Phase 3 PHOENYCS FLY topline readout, which Biogen guided for the first half of December 2026 on its Q3 earnings call. A positive result would strengthen the case for regulatory filings in SLE; a miss would raise doubts about the drug's profile despite PHOENYCS GO's success. Watch for the readout timing and any pre-announcement.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $254.87entry
- T+1 · 7d ago −0.64%α −0.27% · $253.25
- T+5 · 15h ago −1.26%α +0.43% · $251.65
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen and UCB presented post-hoc analyses of the Phase 3 PHOENYCS GO trial of dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) at ACR Convergence 2026. The data showed DZP plus standard of care was associated with higher response rates on the novel TRM-SLE measure and greater rates of sustained low disease activity and remission versus placebo. DZP remains investigational and not approved by any health authority.
Key Facts
- Post-hoc analysis of Phase 3 PHOENYCS GO using TRM-SLE showed DZP plus SOC vs placebo plus SOC achieved TRM-SLE-50 (61.2% vs 43.2%) and TRM-SLE-100 (52.5% vs 36.8%) through Week 48.
- Sustained LLDAS at Weeks 40/44/48: DZP 24.0% vs placebo 10.3% (nominal p=0.0012); sustained DORIS: 11.5% vs 4.7% (nominal p=0.0253).
- Primary endpoint BICLA response at Week 48 was met (50% vs 35%; p=0.011) as previously reported in The Lancet.
- DZP is an investigational biologic not approved by any health authority worldwide.
- Data presented across five posters at ACR Convergence 2026.
Financial Impact
No financial figures stated; DZP is in Phase 3 development and not yet approved or generating revenue.
Risk Factors
- All data are post-hoc analyses; TRM-SLE is a novel measure not yet validated as a primary endpoint by regulators.
- DZP is not approved and may never receive regulatory approval; safety and efficacy not established.
- Competition from approved SLE therapies (e.g., belimumab, anifrolumab) and other pipeline candidates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398047 |
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers